KITABIS PAK vs MYCIFRADIN

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated June 7, 2026·How we rate

Possible drug interaction. KITABIS PAK and MYCIFRADIN are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KITABIS PAK	MYCIFRADIN
Rating	New	New
Pharmacy pays	$1.08 /mL	~$25.36 /30
Type	RX	RX
Active ingredient	TOBRAMYCIN	NEOMYCIN SULFATE
Manufacturer	Pulmoflow Inc	Pharmacia and Upjohn
Dosage forms	Solution	Tablet, Solution
Drug class	Aminoglycoside Antibacterial	Aminoglycoside Antibacterial
Boxed warning	None	None
Treats	Infectious Bone Diseases, Central Nervous System Infections, Pseudomonas Infections	Escherichia Coli Infections, Hepatic Encephalopathy, Bacterial Skin Diseases

kitabis pak mycifradin

Rating

New

Pharmacy pays

$1.08 /mL

~$25.36 /30

Type

Active ingredient

TOBRAMYCIN

NEOMYCIN SULFATE

Manufacturer

Pulmoflow Inc

Pharmacia and Upjohn

Dosage forms

Solution

Tablet, Solution

Drug class

Aminoglycoside Antibacterial

Boxed warning

None

Treats

Infectious Bone Diseases, Central Nervous System Infections, Pseudomonas Infections

Escherichia Coli Infections, Hepatic Encephalopathy, Bacterial Skin Diseases

Frequently asked questions

What is the difference between Kitabis Pak and Mycifradin?

Kitabis Pak contains Tobramycin, while Mycifradin contains Neomycin Sulfate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.